CRISPR Therapeutics AG [CRSP] stock is trading at $57.90, up 1.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRSP shares have gain 9.04% over the last week, with a monthly amount drifted -7.08%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On December 11, 2023, downgrade downgraded it’s rating to Underperform but maintained its price target of $30 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. Mizuho initiated its recommendation with a Buy and recommended $82 as its price target on September 27, 2023. Citigroup upgraded its rating to Buy for this stock on August 17, 2023. In a note dated May 30, 2023, William Blair initiated an Outperform rating and provided a target price of $75 on this stock.
CRISPR Therapeutics AG [CRSP] stock has fluctuated between $37.55 and $91.10 over the past year. Currently, Wall Street analysts expect the stock to reach $124.64 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $57.90 at the most recent close of the market. An investor can expect a potential return of 115.27% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 271.71M for the trailing twelve months, which represents a drop of -99.50%. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -1.1%, Pretax Profit Margin comes in at -0.79%, and Net Profit Margin reading is -0.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.12 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 56.74 points at the first support level, and at 55.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.95, and for the 2nd resistance point, it is at 60.00.
Ratios To Look Out For
For context, CRISPR Therapeutics AG’s Current Ratio is 17.81. As well, the Quick Ratio is 17.81, while the Cash Ratio is 5.95. Considering the valuation of this stock, the price to sales ratio is 18.10, the price to book ratio is 2.36.
Transactions by insiders
Recent insider trading involved Bruno Julianne, Chief Operating Officer, that happened on Jun 21 ’24 when 3366.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Apr 15 ’24 to sell 19582.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 20000.0 shares on Mar 15 ’24.
